Sonendo, Inc.

As of May 10, 2022, Sonendo, Inc. is considered risky and overvalued due to negative financial ratios, with a current price of $0.25 significantly lower than its 52-week high of $11.74, indicating challenges in attracting investor confidence compared to industry peers.

As of May 10, 2022, Sonendo, Inc. is considered undervalued and classified as "risky" due to its low price-to-book value and EV to sales ratio, despite severe financial distress indicated by negative ROCE and ROE metrics.

As of June 11, 2025, Sonendo, Inc. exhibits a bearish technical trend with moderate strength, driven by bearish daily moving averages and KST indicators, despite some mildly bullish signals from the MACD.

Sonendo, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $8 million and a net loss of $6 million as of December 2024. Key metrics include a market cap of $0.49 million, a debt-to-equity ratio of 0.75, and a return on equity of -614.16%.

As of Jun 17, Sonendo, Inc. has a market capitalization of 0.49 million, with net sales of 31.70 million and a net profit of -33.55 million over the latest four quarters. Shareholder's funds are reported at 5.19 million, and total assets amount to 31.27 million.